Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company that regularly issues news and updates about its inflammation and immunology pipeline targeting the innate immune system. This news page aggregates company press releases and third-party coverage related to INmune Bio’s DN-TNF platform, CORDStrom™ mesenchymal stromal cell platform, and INKmune® natural killer cell priming platform.
Readers can find updates on XPro™ (XPro1595, pegipanermin), a selective soluble TNF neutralizer that the company is developing for neurological diseases driven by chronic inflammation. Recent news has highlighted Phase 2 MINDFuL trial results in early Alzheimer’s disease with inflammatory biomarkers, neuroimaging analyses using advanced MRI techniques, and manuscript submissions to peer-reviewed journals. The company also reports on scientific presentations at conferences such as the Clinical Trials on Alzheimer’s Disease (CTAD) meeting and the Alzheimer’s Association International Conference.
News related to the CORDStrom™ cell therapy platform includes clinical and manufacturing milestones in recessive dystrophic epidermolysis bullosa (RDEB), such as completion of a blinded randomized trial, pilot-scale commercial manufacturing runs at a cell and gene therapy manufacturing center in the United Kingdom, and intellectual property developments. INmune Bio also issues updates on participation in industry events and panels focused on dermatologic rare diseases and cell therapy manufacturing.
For the INKmune® platform, news items cover progress in the CaRe PC Phase I/II trial in metastatic castration-resistant prostate cancer, including reports that the trial met its primary and certain secondary endpoints, safety observations, and biomarker findings related to NK cell activation. Corporate news, including financing transactions, management changes, and special stockholder meetings, is also disclosed through regular press releases and corresponding SEC filings. Investors and researchers can use this page to follow INMB news on clinical data, regulatory plans, manufacturing scale-up, and corporate developments.
INmune Bio, Inc. (NASDAQ: INMB) announced its second Phase 2 trial of XPro for Mild Cognitive Impairment (MCI), alongside a previously disclosed trial for mild Alzheimer’s disease (AD). The trial aims to include 90 patients and assess cognition using the Early AD/MCI Alzheimer's Cognitive Composite (EMACC). As of September 30, 2021, the company reported cash equivalents of $84.5 million and a net loss of approximately $9.5 million for Q3 2021. The firm is also advancing its INKmune™ platform and plans to host a conference call on November 3, 2021.
INmune Bio, Inc. (NASDAQ: INMB) is set to present multiple findings at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, taking place from November 9-12 in Boston. Key presentations include a late-breaking oral presentation on the Early Mild Alzheimer’s Cognitive Composite as a primary cognitive endpoint in a phase 2 trial of XPro1595. Additionally, various poster sessions will examine neuroinflammation biomarkers, imaging measures, and methodologies for effective trial planning. XPro1595 aims to decrease neuroinflammation, potentially improving outcomes in Alzheimer's patients.
INmune Bio, Inc. (NASDAQ: INMB) announced a conference call scheduled for November 3, 2021 at 4:30 PM ET to discuss its third quarter results ending September 30, 2021, and provide a corporate update. The call will offer insights into the company’s clinical-stage immunology initiatives, including its DN-TNF and Natural Killer Cell Priming platforms. Investors can participate via phone or a live audio webcast, with a replay available until November 10. The company emphasizes the forward-looking nature of its statements regarding clinical trials and potential product approvals.
INmune Bio, Inc. (NASDAQ: INMB) announced that Mark Lowdell, PhD, Chief Scientific Officer and Chief Medical Officer, will participate in an oncology panel titled Improving Strategies to Harness the Immune System at the B. Riley Fall 2021 Best Ideas in Oncology Series.
The panel is scheduled for September 30, 2021, at 9:00am ET and is open to institutional investors. Registration is available here.
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company, announced that its President and CEO, Raymond J. Tesi, MD, will present at two investor conferences in September 2021. The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will take place on September 22 at 1:15 PM ET, followed by the Cantor Fitzgerald Global Healthcare Conference on September 29 at 3:20 PM ET. Investors can arrange virtual one-on-one meetings through Oppenheimer or Cantor Fitzgerald. INmune Bio develops treatments targeting the innate immune system for various diseases.
INmune Bio has announced significant results from its Phase 1 study for XPro™, a selective DN-TNF inhibitor aimed at treating Alzheimer's disease (AD). The treatment resulted in a 46% decrease in CSF pT217, a promising biomarker for AD, and improved MRI metrics indicate remyelination. This data demonstrates reductions in biomarkers associated with neuroinflammation and neurodegeneration. A Phase 2 trial is set to begin by the end of 2021, enrolling 200 patients. Preliminary findings will be discussed in a webinar on September 7, 2021.
INmune Bio, Inc. (NASDAQ: INMB) announced positive results from the first patient receiving INKmune™ for high-risk myelodysplastic syndrome (MDS). The therapy successfully activated natural killer (NK) cells, generating memory-like NK (mlNK) cells as predicted by in vitro studies. The patient showed no adverse symptoms of Cytokine Release Syndrome (CRS) and had a doubling of NK cell numbers by day 8. The results indicate INKmune™ can effectively convert resting NK cells into more potent cancer-fighting cells, with further trials planned for additional patients.
INmune Bio, Inc. (NASDAQ: INMB) announced that President and CEO Raymond J. Tesi will present at the Canaccord Genuity 41st Annual Growth Conference from August 10 to 12, 2021. Tesi's presentation is scheduled for August 11, 2021, at 9:00 AM ET. The conference will also allow for virtual one-on-one meetings with INmune Bio representatives. The company focuses on developing treatments to enhance the innate immune system to combat diseases, with key product platforms aimed at various conditions including COVID-19, cancer, and Alzheimer's.
INmune Bio, Inc. (NASDAQ: INMB) announced that its President and CEO, Raymond J. Tesi, MD, will present at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 1:00 PM Eastern Time. The conference will be held virtually on August 9-10, and attendees can schedule one-on-one meetings with INmune Bio through their BTIG representatives.
INmune Bio focuses on developing treatments that leverage the innate immune system to combat diseases, with ongoing clinical trials for various innovative therapies.
INmune Bio, Inc. (NASDAQ: INMB) reported its Q2 2021 financial results and provided a business update on August 4, 2021. The company is progressing towards a Phase 2 clinical trial of XPRO™ in mild Alzheimer’s patients, aiming to start by year-end. Recent financial highlights include a net loss of $6.7 million and increased R&D expenses of $4.5 million. The company raised $51.9 million in July 2021, securing funding for its upcoming trials. Notably, the first patient has been treated in the Phase 1 trial of INKmune for high-risk myelodysplastic syndrome.